#1 Clinical Trials Search in Europe

Fludarabine

Fludarabine is a chemotherapy drug that is being studied in clinical trials for treating several types of cancer and blood disorders. These trials are exploring how fludarabine can be used alone or in combination with other treatments to improve outcomes for patients with conditions like leukemia, lymphoma, multiple myeloma, and sickle cell disease. Researchers are investigating different dosing regimens, administration methods, and combination therapies to determine the most effective and safe ways to use fludarabine for various conditions.

Table of Contents

What is Fludarabine?

Fludarabine is a chemotherapy drug used to treat various blood cancers and disorders. It’s also known by other names such as Fludara, 2-Fluoro-ara-A Monophosphate, 2-Fluoro-ara AMP, or FAMP[1]. This medication belongs to a class of drugs called purine analogs, which work by interfering with the growth of cancer cells[2].

What Conditions Does Fludarabine Treat?

Fludarabine is used to treat several blood-related cancers and disorders, including:

  • Chronic Lymphocytic Leukemia (CLL): A slow-growing cancer of the blood and bone marrow[3]
  • Acute Myeloid Leukemia (AML): A fast-growing cancer of the blood and bone marrow[4]
  • Non-Hodgkin’s Lymphoma: A group of blood cancers that start in the lymphatic system[5]
  • Myelodysplastic Syndrome (MDS): A group of disorders where blood cells don’t mature properly in the bone marrow[6]

How Does Fludarabine Work?

Fludarabine works by interfering with the DNA synthesis of cancer cells. It does this by:

  • Inhibiting an enzyme called DNA polymerase, which is crucial for DNA replication
  • Incorporating itself into the DNA of cancer cells, causing them to stop dividing
  • Triggering cell death (apoptosis) in cancer cells
This mechanism of action helps to slow down or stop the growth of cancer cells in the body[2].

How is Fludarabine Administered?

Fludarabine is typically administered in the following ways:

  • Intravenous (IV) infusion: The drug is given directly into a vein over a period of 30 minutes to an hour[3]
  • Oral tablets: In some cases, fludarabine may be given as pills to be taken by mouth

The dosage and schedule can vary depending on the specific condition being treated, the patient’s overall health, and other factors. For example, in one study, patients received fludarabine at a dose of 25 mg/m² on days 1-3 of their treatment cycle[7].

Fludarabine in Combination Therapies

Fludarabine is often used in combination with other drugs to enhance its effectiveness. Some common combination therapies include:

  • Fludarabine, Cyclophosphamide, and Rituximab (FCR): This combination is commonly used for treating chronic lymphocytic leukemia[3]
  • Fludarabine and Busulfan: Used in preparation for stem cell transplants in patients with blood cancers[8]
  • Fludarabine and Cytarabine: This combination is sometimes used to treat acute myeloid leukemia, especially in older patients[4]

Potential Side Effects

Like all chemotherapy drugs, fludarabine can cause side effects. Some potential side effects include:

  • Lowered blood counts: This can increase the risk of infections, anemia, and bleeding
  • Nausea and vomiting
  • Fatigue
  • Weakened immune system

Your healthcare team will monitor you closely for these and other side effects during treatment[3].

Ongoing Clinical Trials

Researchers continue to study fludarabine to improve its effectiveness and explore new uses. Some ongoing clinical trials are investigating:

  • The use of fludarabine in combination with other drugs for various blood cancers[7]
  • Fludarabine as part of conditioning regimens for stem cell transplants[8]
  • The effectiveness of fludarabine-based therapies compared to newer treatments[4]

These studies aim to find better ways to use fludarabine and improve outcomes for patients with blood cancers and disorders.

Aspect Details
Main uses in trials Treatment of blood cancers, conditioning for stem cell transplants
Administration methods Intravenous infusion, oral tablets
Common combinations With cyclophosphamide, melphalan, ATG for transplant conditioning
Dosing strategies Multiple days per cycle, repeated cycles, dose escalation studies
Key outcome measures Safety/toxicity, engraftment, response rates, survival
Patient populations Adults and children with various cancers and blood disorders
Novel approaches Gene-modified T-cell therapies, reduced-intensity transplant regimens

FAQ

  • What is fludarabine and how does it work? Fludarabine is a chemotherapy drug that interferes with DNA synthesis in cancer cells. It is classified as a purine analog and works by inhibiting DNA repair and replication, which can kill cancer cells or stop them from growing.
  • What conditions is fludarabine being studied to treat in clinical trials? Clinical trials are investigating fludarabine for treating various blood cancers like chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and acute myeloid leukemia. It's also being studied for use in stem cell transplants for conditions like sickle cell disease and multiple myeloma.
  • How is fludarabine typically administered in clinical trials? In most trials, fludarabine is given intravenously (through an IV) or orally (by mouth) for several days as part of a treatment cycle. The exact dosing and schedule varies depending on the specific trial and condition being treated.
  • What are some potential side effects of fludarabine? Common side effects may include nausea, fatigue, and increased risk of infections. More serious side effects can include low blood cell counts, nerve problems, and rarely, severe brain or neurological effects. Side effects are closely monitored in clinical trials.
  • How long do patients typically receive fludarabine in clinical trials? The duration of treatment varies widely between trials. Some involve just a few days of fludarabine as part of pre-transplant conditioning, while others may give repeated cycles over several months. The exact length depends on the trial design and how patients respond.

Ongoing Clinical Trials on Fludarabine

  • Study on the Effectiveness and Safety of Lifileucel and Pembrolizumab for Patients with Untreated, Unresectable, or Metastatic Melanoma

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia Finland France Germany Greece +6

  • Study Comparing Clofarabine/Busulfan and Fludarabine/Busulfan for Adults with Acute Myeloid Leukemia Eligible for Stem Cell Transplantation

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Austria Belgium Denmark France Germany Italy +3

  • Study of Ciltacabtagene Autoleucel and Drug Combination for Treatment of High-Risk Smoldering Multiple Myeloma

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Safety and Effectiveness of Anitocabtagene Autoleucel and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Spain

  • Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Bulgaria Czechia Denmark France Germany +7

  • Study of ARI-0001 Cells for Children and Adolescents with Resistant or Refractory Acute Lymphoblastic Leukemia

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Spain

  • Study on the Effectiveness and Safety of OTL-203 for Patients with Hurler Syndrome (MPS-IH) Compared to Standard Treatment with Stem Cell Transplantation

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Italy The Netherlands

  • Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Austria Czechia Germany Italy Poland Slovenia

  • Study on Brexucabtagene Autoleucel for Adults with Relapsed or Refractory Burkitt Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Italy The Netherlands Spain +1

Glossary

  • Hematopoietic stem cell transplant (HSCT): A procedure where healthy blood-forming stem cells are transplanted to replace diseased or damaged bone marrow. It's used to treat various blood disorders and cancers.
  • Graft-versus-host disease (GVHD): A potential complication of stem cell transplants where the donor cells attack the recipient's body. Medications are given to help prevent and treat GVHD.
  • Non-myeloablative conditioning: A less intense form of pre-transplant treatment that doesn't completely destroy the bone marrow. It may have fewer side effects than traditional high-dose conditioning.
  • Chimerism: The presence of donor-derived cells in a transplant recipient. Mixed chimerism means both donor and recipient cells are present.
  • Relapsed/Refractory: Refers to cancer that has returned after treatment (relapsed) or did not respond to initial treatment (refractory).
  • Indolent lymphoma: A slow-growing type of lymphoma that often has few symptoms in early stages.
  • Myelodysplastic syndrome (MDS): A group of disorders where the bone marrow doesn't produce enough healthy blood cells.
  • Dose-limiting toxicity (DLT): Side effects severe enough to prevent increasing the dose of a drug in a clinical trial.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the disease getting worse.
  • Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.

References

  1. https://clinicaltrials.gov/study/NCT02057770
  2. https://clinicaltrials.gov/study/NCT01124526
  3. https://clinicaltrials.gov/study/NCT00280241
  4. https://clinicaltrials.gov/study/NCT02319135
  5. https://clinicaltrials.gov/study/NCT00002779
  6. https://clinicaltrials.gov/study/NCT00048412
  7. https://clinicaltrials.gov/study/NCT06581562
  8. https://clinicaltrials.gov/study/NCT01366612